Menu
Not yet recruiting NCT07665866

Suivi Prospectif Des ostéomyélites de la Base du crâne

Observational Malignant External Otitis (Necrotizing/Malignant Otitis Externa) Central Skull Base Osteomyelitis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Malignant External Otitis (Necrotizing/Malignant Otitis Externa), Central Skull Base Osteomyelitis. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

Skull base osteomyelitis (SBO) is a rare and complex infection that includes malignant external otitis and central skull base osteomyelitis. Symptoms are often non-specific, and the disease typically progresses slowly, leading to delays in diagnosis and treatment, as well as local or regional complications. Management is not standardized and consists of medical treatment tailored to microbiological sampling results (antibiotic or antifungal therapy). Monitoring strategies and treatment modalities, particularly treatment duration, have not been standardized. Given the rarity of these infections, it is currently very difficult to conduct prospective studies comparing different management approaches.

Detailed description

This will be a prospective multicenter study involving departments of Otorhinolaryngology (ENT), Infectious Diseases, Diabetology, and Internal Medicine.

Patients receiving care for skull base osteomyelitis who are seen either in outpatient consultation or during hospitalization will be included in the study, provided that their non-objection to participation has been obtained.

Patients will be managed and monitored according to standard clinical practice (routine care).

Primary outcome measures

  • One-year prognosis of skull base osteomyelitis [Time frame: 1 year]

Eligibility criteria

Inclusion criteria

  • Participants must meet all of the following criteria:
  • Age ≥ 18 years.
  • Diagnosis of skull base osteomyelitis, based on the combination of:
  • Clinical signs: otorrhea and/or otalgia and/or granulation tissue in the external -auditory canal, headache(s) and/or paralysis of one or more cranial nerves;
  • AND radiological findings: bone destruction/osteolysis demonstrated on CT scan and/or MRI.

Exclusion criteria

  • Participants meeting any of the following criteria will be excluded:

Expressed refusal (objection) to participate in the study. Individuals under legal protection measures (guardianship, curatorship, or judicial protection).

Patients managed for osteoradionecrosis. Patients managed for squamous cell carcinoma of the external auditory canal.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

France · 1 center
  • Lariboisière Hospital, 2 rue Ambroise Paré — Paris

Identifiers

NCT: NCT07665866 · APHP251672

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗